San Diego, CA -- (SBWIRE) -- 01/12/2016 -- An investigation for shareholders in Northwest Biotherapeutics, Inc (NASDAQ:NWB) concerning potential breaches of fiduciary duties by certain Northwest Biotherapeutics directors was announced.

Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) declined from over $12 per share in July 2015 to as low as $2.11 per share on January 7, 2016.

Investors who are current long term investors in Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm for current long term investors in NASDAQ:NWBO stocks follows a lawsuit filed against Northwest Biotherapeutics, Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:NWBO stocks, concerns whether certain Northwest Biotherapeutics officers and directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges that between March 8, 2013 and August 20, 2015 Defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose that Northwest Biotherapeutics' claims regarding positive results from its DCVax-Direct Trial were based on preliminary and unconfirmed trial results, that the DCVax-Direct Trial results on which Northwest Biotherapeutics reported had not been reviewed or analyzed by the hospitals conducting the trials, that Northwest Biotherapeutics' statements about DCVax-Direct were derived from patient case report forms, which the hospitals were obliged to send to the Company only because it sponsored the study, that Northwest Biotherapeutics was the subject of an aggressive stock promotion campaign which included promoters using fictitious identities and false credentials, that German regulators required additional information from Northwest Biotherapeutics in order for its DCVax-L Trial to continue uninterrupted, and that as a result of the above, Northwest Biotherapeutics' financial statements were materially false and misleading at all relevant times.

On June 19, 2014, an article was published that stated that "The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct."

On July 7, 2014, a report published stated that Northwest Biotherapeutics, Inc has been the subject of a massive promotional campaign which has seen the stock price soar. And, in some cases, authors have used fictitious identities and fake credentials within healthcare or finance. In fact they are simply paid writers. On this news, shares of Northwest Biotherapeutics, Inc fell $0.52 per share to $6.62 in intraday trading on July 7, 2014.

On August 21, 2015, pre-market, news broke that Northwest Biotherapeutics, Inc's Phase 3 DCVax-L brain cancer treatment clinical trial in Germany was temporarily halted. A reason is yet to be provided, and Northwest Biotherapeutics is yet to address the issue publicly. Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) declined to as low as $6.64 per share on August 24, 2015,.

Those who purchased shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com